Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaPRADOS, Michael D; CHANG, Susan M; FEDOROFF, Anne et al.Journal of clinical oncology. 2009, Vol 27, Num 4, pp 579-584, issn 0732-183X, 6 p.Article

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiformeCHANG, Susan M; LAMBORN, Kathleen R; MALEC, Mary et al.International journal of radiation oncology, biology, physics. 2004, Vol 60, Num 2, pp 353-357, issn 0360-3016, 5 p.Article

Temozolomide in the treatment of recurrent malignant gliomaCHANG, Susan M; THEODOSOPOULOS, Philip; LAMBORN, Kathleen et al.Cancer. 2004, Vol 100, Num 3, pp 605-611, issn 0008-543X, 7 p.Article

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiformePRADOS, Michael D; WARA, William M; LAMBORN, Kathleen et al.International journal of radiation oncology, biology, physics. 2001, Vol 49, Num 1, pp 71-77, issn 0360-3016Article